Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

anti-programmed cell death 1/ligand-1 antibodies

  • You have access
    Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
    TAKEHIRO TOZUKA, NORIKO YANAGITANI, HIROSHI YOSHIDA, RYO MANABE, SHINSUKE OGUSU, RYOSUKE TSUGITOMI, HIROAKI SAKAMOTO, YOSHIAKI AMINO, RYO ARIYASU, KEN UCHIBORI, SATORU KITAZONO, MASAHIRO SEIKE, AKIHIKO GEMMA and MAKOTO NISHIO
    Anticancer Research April 2021, 41 (4) 2093-2100; DOI: https://doi.org/10.21873/anticanres.14980
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire